Mymetics Corporation
Mymetics Corporation Presents Ground Breaking Results With Preventative HIV Vaccine at the World AIDS Vaccine Congress in Paris 19 – 22 October
Mymetics Corporation / 20.10.2009 Dissemination of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. --------------------------------------------------------------------------- EPALINGES, Switzerland, Oct. 20, 2009 (GLOBE NEWSWIRE) -- Mymetics Corporation(OTCBB:MYMX), a pioneer in the development of mucosal focused vaccines forhuman infectious diseases, announced today that the company had been selectedto present their ground breaking results obtained for their preventative HIV-1vaccine. The poster is titled 'High Protection of Female Macaques from RepeatedIntra-Vaginal Challenges with Low-dose of SHIV(SF162P3) upon MucosalVaccination with Gp41 subunits-Virosomes inducing Gp41-specific Mucosal ImmuneResponses'. Results show high mucosal protection against repeated live SHIVvaginal challenges after vaccination with Mymetics' preventative HIV-1 vaccinecandidate. The vaccinated group showed no detectable viremia while the placebogroup became fully infected. 'We are very pleased to share our results with the scientific communityattending to the world leading congress on AIDS vaccines,' commented Dr.Sylvain Fleury, Chief Scientific Officer of Mymetics Corp; 'The results arevery encouraging and we believe Mymetics' approach is opening the door to thedevelopment of preventative HIV-1 vaccine through mucosal defense mechanism.' About MymeticsSwiss based, U.S. biotechnology company (OTCBB:MYMX), focused on thedevelopment of the next generation preventative vaccines for infectiousdiseases, with 5 vaccines in the pipeline: HIV-1/AIDS, Influenza, RespiratorySyncytial Virus, Malaria and Herpes Simplex Virus. Mymetics core technology andknow-how is based on the use of virosomes as a vaccine delivery platformcombined with rationally designed antigens to induce protection acting on earlytransmission and infection events, including the mucosal immune response as afirst barrier against the infection. Mymetics believes that this platformallows it to develop preventative vaccines for a broad range of diseases. Mymetics will start the Phase I for HIV-1 vaccine. The Malaria vaccine is atthe end of a Phase 1b trial with children in Tanzania, while the RSV and theHSV vaccine candidates are in pre-clinical phase. The Influenza virus isout-licensed to Solvay Pharmaceuticals. For further information, please visit:www.mymetics.com The Mymetics Corporation logo is available athttp://www.globenewswire.com/newsroom/prs/?pkgid=5478 Forward looking statementsThe Private Securities Litigation Reform Act of 1995 provides a 'safe harbor'for forward-looking statements, which are identified by the words 'believe,''expect,' 'anticipate,' 'intend,' 'plan' and similar expressions. Thestatements contained herein which are not based on historical facts areforward-looking statements that involve known and unknown risks anduncertainties that could significantly affect our actual results, performanceor achievements in the future and, accordingly, such actual results,performance or achievements may materially differ from those expressed orimplied in any forward-looking statements made by or on our behalf. These risksand uncertainties include, but are not limited to, risks associated with ourability to successfully develop and protect our intellectual property, ourability to raise additional capital to fund future operations and compliancewith applicable laws and changes in such laws and the administration of suchlaws. See Mymetics' most recent Form 10-K for a discussion of such risks,uncertainties and other factors. Readers are cautioned not to place unduereliance on these forward- looking statements which speak only as of the datethe statements were made. CONTACT: Mymetics Corporation Ronald Kempers +41 21 653 4535 News Source: NASDAQ OMX 20.10.2009 financial News transmitted by DGAP --------------------------------------------------------------------------- Language: English Company: Mymetics Corporation CH Phone: Fax: E-mail: Internet: ISIN: US62856A1025 WKN: End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden